BD Expands Smart Monitoring Portfolio with Edwards Lifesciences’ Critical Care Acquisition

In a strategic expansion of its medical technology offerings, BD (Becton, Dickinson and Company) (NYSE: BDX) announced in September the completion of its acquisition of Edwards Lifesciences’ (NYSE: EW) Critical Care product line, now rebranded as Advanced Patient Monitoring. This move strengthens BD’s portfolio of smart, connected care solutions, integrating a leading suite of monitoring technologies, AI-driven clinical decision tools, and a robust pipeline of innovative solutions.

Now integrated into BD Medical, BD’s largest revenue-contributing segment—comprising approximately 50% of its total revenue in 2024—the Advanced Patient Monitoring unit is projected to be a key growth driver. Visible Alpha consensus forecasts that the unit’s revenue will climb from  $74 million in 2024 to $1 billion by 2025. For Edwards Lifesciences, the divestiture is anticipated to result in a -3.2% year-over-year decline in total revenue for 2024, dropping to $5.8 billion. However, with a refocus on high-growth segments such as Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT), analysts expect the company to resume revenue growth of +1.8% in 2025, with robust gains anticipated from 2026 onward.